subjects with signs of active sars-cov-2 infection at the screening visit subjects with a history of sars-cov-2 infection based on a positive pcr test result after the second dose of the primary vaccination subjects with an active cmv infection that requires treatment subjects who have received rituximab within 6 months prior to the screening visit subjects who have received intravenous immune globulin (ivig) within 6 months prior to the screening visit subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products. subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study. subjects who have experienced transplant rejection within 30 days prior to the screening visit subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion.

subjects with signs of active sars-cov-2 infection at the screening visit subjects with a history of sars-cov-2 infection based on a positive pcr test result after the second dose of the primary vaccination subjects with an active cmv infection that requires treatment subjects who have received rituximab within 6 months prior to the screening visit subjects who have received intravenous immune globulin (ivig) within 6 months prior to the screening visit subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products. subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study. subjects who have experienced transplant rejection within 30 days prior to the screening visit subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion.